Moreover, it is unclear whether the increased mortality risk associated with atherogenic dyslipidaemia is attributable to increased triglycerides or decreased HDL cholesterol per se or to the related changes in TRLs (and remnant cholesterol content) or HDL function and size, respectively, which however may not be accurately reflected in the lipid profile and might be better predicted by ApoB and ApoA-I, respectively [38]. This evidence concerns the gene APOB and inherited lipid metabolism disorder.